Sepsis and Critical Illness in Babies > 34 Weeks Gestation
Sepsis and Critical Illness in Babies > 34 Weeks Gestation
批准号:
7290973
负责人:
GABRIEL J. ESCOBAR
金额:
$43.7万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-30 至 2009-08-31
关键词:
AddressAgeAmbulancesAntibiotic TherapyAntibioticsBacterial InfectionsBiometryBirthBloodBlood gasBostonCaliforniaCaringCerebrospinal FluidChestClinicalCollaborationsCommunicable DiseasesComplete Blood CountCritical IllnessCross-Sectional StudiesDataDeteriorationDevelopmentDiagnostic testsElectronicsEnvironmental air flowEpidemiologyEpidural AnesthesiaEvaluationExtracorporeal Membrane OxygenationFederal GovernmentFrequenciesFundingGestational AgeGoalsHealthy People 2010HelicopterHospitalsHourInfantInfant MortalityInfectionInfection of amniotic sac and membranesJointsLaboratoriesLifeLiteratureLive BirthMaternal and Child HealthMedicalMedicineMeningitisModelingMorbidity - disease rateNeonatalNeonatal Intensive Care UnitsNeonatologyNested Case-Control StudyNewborn InfantPaperPatient observationPopulationPre-EclampsiaPregnancyProbabilityProcessRecommendationRecordsResearchResearch PersonnelRespiratory FailureRespiratory distressRiskRisk FactorsSamplingSan FranciscoSepsisShockSymptomsTestingTextbooksTriageUniversitiesWeekWorkYinbasecase controldesignearly onsetimprovedinhaled nitric oxideneutrophilprogramstertiary care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Confirmed neonatal bacterial infections occur in 1-5 per 1000 live births. However, in the US about 10-20 percent of newborns have "sepsis work-ups" done, and 4-10 percent receives systemic antibiotics. Textbooks recommend antibiotic therapy for infants with definite signs of sepsis, meningitis, shock, or respiratory failure. They do not provide evidence-based guidance for the evaluation and management of two common groups of term or near-term newborns: 1) infants with maternal risk factors for bacterial infection (e.g., chorioamnionitis) with no symptoms or who have presentations that are considered equivocal, and 2) infants with respiratory distress, which occurs in approximately 2-3 percent of term and near-term infants. Clinicians evaluating term or near term infants must make 3 decisions: 1) whether to obtain laboratory tests; 2) whether to treat with antibiotics, and 3) whether to transfer the infant to a tertiary care center. We propose to improve the evaluation and management of newborns >= 34 weeks gestation at risk for bacterial infection and/or critical illness by developing an evidence-based approach to estimating probabilities relevant to each of these decisions. We will integrate gestational age-specific prior probabilities with likelihood ratios for maternal risk factors, clinical signs, and age-specific laboratory results. To achieve this goal, we have these Specific Aims: 1) To perform a nested case-control study to quantify maternal and infant clinical risk factors for early onset bacterial infection; 2) To perform a retrospective cross-sectional study to estimate likelihood ratios for early onset bacterial infection for components of the complete blood count (CBC, the most common diagnostic test in this setting), using data from more than 40,000 CBCs and blood cultures from 14 hospitals; and (3) To perform a nested case control study to develop a quantitative model to estimate the probability of newborns >= 34 weeks gestation developing a critical illness (defined by life-threatening arterial blood gas results) based on clinical findings and the results of laboratory tests, including arterial blood gases. To achieve these aims, we will analyze paper and electronic records from 340,000 newborns >= 34 weeks gestation born from 1998 to 2005 at 14 hospitals in Northern California and Boston. Our project builds on considerable development work conducted by investigators at Kaiser Permanente's Division of Research, the University of California, San Francisco, and the Harvard Newborn Medicine Program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rapid Clinical Snapshots from the EMR among Pneumonia Patients
-
批准号:8111670
-
项目类别:
-
资助金额:$49.11万
-
财政年份:2009
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
Rapid Clinical Snapshots from the EMR among Pneumonia Patients
-
批准号:7934624
-
项目类别:
-
资助金额:$48.67万
-
财政年份:2009
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
Rapid Clinical Snapshots from the EMR among Pneumonia Patients
-
批准号:7785886
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2009
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
Sepsis and Critical Illness in Babies > 34 Weeks Gestation
-
批准号:7090169
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2006
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
Sepsis and Critical Illness in Babies > 34 Weeks Gestation
-
批准号:7474017
-
项目类别:
-
资助金额:$42.43万
-
财政年份:2006
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
HOW MUCH DOES SHE REALLY DRINK? AN HMO INTERVENTION
-
批准号:6468335
-
项目类别:
-
资助金额:$3.96万
-
财政年份:1999
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
HOW MUCH DOES SHE REALLY DRINK? AN HMO INTERVENTION
-
批准号:6371599
-
项目类别:
-
资助金额:$22.39万
-
财政年份:1999
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
HOW MUCH DOES SHE REALLY DRINK? AN HMO INTERVENTION
-
批准号:6509062
-
项目类别:
-
资助金额:$28.32万
-
财政年份:1999
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
HOW MUCH DOES SHE REALLY DRINK? AN HMO INTERVENTION
-
批准号:6745307
-
项目类别:
-
资助金额:$3.85万
-
财政年份:1999
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
HOW MUCH DOES SHE REALLY DRINK--HMO INTERVENTION
-
批准号:6051728
-
项目类别:
-
资助金额:$30.28万
-
财政年份:1999
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
HOW MUCH DOES SHE REALLY DRINK? AN HMO INTERVENTION
-
批准号:6168525
-
项目类别:
-
资助金额:$21.9万
-
财政年份:1999
-
负责人:GABRIEL J. ESCOBAR
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: